Thromboprophylaxis in people hospitalized with COVID-19: Assessing intermediate or standard doses in a retrospective cohort study.

Kathleen Michelle AndersenCorey S JosephHemalkumar B MehtaMichael B StreiffJoshua F BetzRobert C BollingerArielle M FisherAmita GuptaCharles F LeMaistreMatthew L RobinsonYanxun XuDerek K NgG Caleb AlexanderBrian T Garibaldi

Published in: Research and practice in thrombosis and haemostasis (2022)

Our findings do not support routine use of intermediate-dose thromboprophylaxis to prevent clinical worsening, severe disease, or death among adults hospitalized with COVID-19.

Keyphrases

coronavirus disease
sars cov
venous thromboembolism
direct oral anticoagulants
early onset
respiratory syndrome coronavirus
clinical practice